VKTX - Viking Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
10.49
-0.25 (-2.33%)
As of 12:53PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close10.74
Open10.74
Bid10.59 x 800
Ask10.59 x 800
Day's Range10.42 - 10.84
52 Week Range0.88 - 13.43
Volume734,212
Avg. Volume3,561,958
Market Cap636.248M
Beta2.68
PE Ratio (TTM)N/A
EPS (TTM)-0.79
Earnings DateAug 7, 2018 - Aug 13, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.40
Trade prices are not sourced from all markets
  • 3 Biotech Stocks With Big News Coming in NASH
    Motley Fool2 days ago

    3 Biotech Stocks With Big News Coming in NASH

    The next big market for biopharma could be nonalcoholic steatohepatitis, so upcoming data from these companies could be market-moving.

  • 3 Top Biotech Stocks to Buy Right Now
    Motley Fool3 days ago

    3 Top Biotech Stocks to Buy Right Now

    This could be a good time to add a profit-friendly play, a clinical-stage upstart, and a make-or-break biotech to your portfolio.

  • 3 Top Biotech Stocks to Buy for the 2nd Half of 2018
    Motley Fool8 days ago

    3 Top Biotech Stocks to Buy for the 2nd Half of 2018

    Consider putting these large-cap, mid-cap, and small-cap biotech stocks on your buy list.

  • Viking Therapeutics, Buy the Dip?
    Motley Fool20 days ago

    Viking Therapeutics, Buy the Dip?

    Viking's shares finally pulled back last week. Should investors take advantage of this dip?

  • This Is the Most Undervalued NASH Drug Stock, and Wall Street Is Ignoring It
    Motley Fool20 days ago

    This Is the Most Undervalued NASH Drug Stock, and Wall Street Is Ignoring It

    This NASH drug developer has a decent chance at beating all of its peers to market.

  • 3 Small-Cap Biotech Stocks to Keep on Your Radar
    Motley Fool26 days ago

    3 Small-Cap Biotech Stocks to Keep on Your Radar

    Small market caps. Big opportunities.

  • Cash for NASH: 2 Top Biotech Takeover Targets and 3 Potential Buyers
    Motley Foollast month

    Cash for NASH: 2 Top Biotech Takeover Targets and 3 Potential Buyers

    These two small biotechs with promising NASH drugs could attract several big suitors.

  • 3 Growth Stocks at Deep-Value Prices
    Motley Foollast month

    3 Growth Stocks at Deep-Value Prices

    Attractively priced stocks with plenty of runway for growth give the best chance for outsized, long-term returns.

  • GlobeNewswirelast month

    Investor Expectations to Drive Momentum within NovoCure, Canada Goose, Telephone and Data, FMC, MobileIron, and Viking Therapeutics — Discovering Underlying Factors of Influence

    NEW YORK, June 15, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of NovoCure ...

  • Why Viking Therapeutics Stock Rose on June 13
    Market Realistlast month

    Why Viking Therapeutics Stock Rose on June 13

    On June 13, Viking Therapeutics (VKTX) stock rose ~9.1%, triggered by positive mid-stage trial results for peer Galmed Pharmaceuticals’ (GLMD) NASH (non-alcoholic steatohepatitis) drug, Aramchol. For more on the development, read Why Galmed Pharmaceuticals Stock Rose 151% on June 12. Galmed’s positive study results buoyed investors’ hopes of success for Viking Therapeutics’ NASH candidate, VK2809, which is in mid-stage trials and has a similar mechanism of action. On June 13, the SPDR S&P Biotech ETF (XBI) rose ~0.26%.

  • Are These Red-Hot NASH Stocks Still a Buy?
    Motley Foollast month

    Are These Red-Hot NASH Stocks Still a Buy?

    Investors are piling into NASH stocks right now, but which ones are the best long-term buys?

  • Here's Why Viking Therapeutics Rose as Much as 14.9% Today
    Motley Foollast month

    Here's Why Viking Therapeutics Rose as Much as 14.9% Today

    The clinical-stage biopharma is on a tear in recent weeks.

  • Zacks Small Cap Researchlast month

    VKTX: Final Patient Enrolled in P2 Trial of VK2809; Raises Gross Proceeds of $77.6M in Public Offering

    Gross proceeds to the company will be approximately $77.6 million. The company exited the first quarter of 2018 with approximately $77.5 million in cash and cash equivalents. Following this most recent financing, we estimate the company will exit the second quarter of 2018 with between $140-$150 million, which should be sufficient to fund operations well into 2020.

  • PR Newswirelast month

    Viking Therapeutics Announces Closing of Public Offering of Common Stock

    Viking currently intends to use the net proceeds from the offering for continued development of its VK2809, VK5211 and VK0214 programs and for general research and development, working capital and general corporate purposes. This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

  • 2 Cheap Growth Stocks to Buy Right Now
    Motley Foollast month

    2 Cheap Growth Stocks to Buy Right Now

    Crispr Therapeutics and Viking Therapeutics are both grossly undervalued relative to their long-term prospects right now.

  • Now's the Time to Buy These 3 Stocks
    Motley Foollast month

    Now's the Time to Buy These 3 Stocks

    There's no need to wait with these three hot stocks.

  • PR Newswirelast month

    Viking Therapeutics Announces Pricing of $67.5 Million Public Offering of Common Stock

    SAN DIEGO, June 7, 2018 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the pricing of its public offering of 7,500,000 shares of its common stock at a price to the public of $9.00 per share. Viking currently intends to use the net proceeds from the offering for continued development of its VK2809, VK5211 and VK0214 programs and for general research and development, working capital and general corporate purposes. In addition, Viking has granted the underwriters a 30-day option to purchase up to 1,125,000 additional shares of its common stock.

  • PR Newswirelast month

    Viking Therapeutics Announces Proposed Public Offering of Common Stock

    SAN DIEGO, June 6, 2018 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. Viking also expects to grant to the underwriters of the offering a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering on the same terms and conditions. All the shares to be sold in the offering are to be sold by Viking.

  • ACCESSWIRElast month

    Viking Therapeutics Recent VK2809 Update, Analyst Review and Target

    NEW YORK, NY / ACCESSWIRE / June 6, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report with no obligation on Viking Therapeutics, Inc. (VKTX), a clinical-stage biopharmaceutical company focused on the development of novel, therapies for metabolic and endocrine disorders. On June 5th, the company announced that enrolment had been completed in the company's ongoing Phase 2 clinical trial of VK2809.

  • ACCESSWIRElast month

    Complimentary Technical Snapshots on Viking Therapeutics and Three More Biotech Stocks

    Shares in Needham, Massachusetts headquartered Verastem Inc. saw a decline of 3.56%, ending Monday's trading session at $5.14. The stock recorded a trading volume of 2.58 million shares, which was higher than its three months average volume of 1.23 million shares.

  • PR Newswirelast month

    Viking Therapeutics Completes Enrollment in Phase 2 Study of VK2809 in Patients with Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease

    The Phase 2 clinical trial is a randomized, double-blind, placebo-controlled, parallel-group study designed to evaluate the efficacy, safety and tolerability of VK2809 in patients with elevated LDL cholesterol (LDL-C) and NAFLD.  Patients have been randomized to receive once-daily oral doses of VK2809 or placebo for 12 weeks followed by a four-week off-drug phase.  The trial's primary endpoint will evaluate the effect of VK2809 treatment on LDL-C after 12 weeks compared to placebo.  Secondary and exploratory endpoints include assessments of changes in liver fat content, triglycerides, and other lipid markers.  Viking expects to announce results from this trial in the second half of 2018.

  • Benzingalast month

    Maxim Explains Viking Therapeutics' Sympathy Move With Madrigal

    Viking Therapeutics Inc (NASDAQ: VKTX ) shares more than doubled Thursday after a 145-percent jump in shares of Madrigal Pharmaceuticals Inc (NASDAQ: MDGL ), which announced data from a Phase 2 study of ...

  • 3 Biotech Stocks That Soared This Week: Are They Buys?
    Motley Foollast month

    3 Biotech Stocks That Soared This Week: Are They Buys?

    Can these three sizzling-hot biotech stocks keep the momentum going?

  • Zacks Small Cap Researchlast month

    VKTX: Positive Data from Madrigal is Positive for Viking; Raising Valuation to $16

    On May 31, 2018, Madrigal Pharmaceuticals, Inc. (MDGL) announced positive results from the Phase 2 trial of MGL-3196, the company’s thyroid hormone receptor beta (TRβ) agonist, in patients with biopsy confirmed nonalcoholic steatohepatitis (NASH). The following table shows that 56% of patients treated with MGL-3196 experienced a ≥ 2 point reduction in NAS, which increased to 70% when only considering those patients that were MGL-3196 MRI-PDFF responders at week 12 (e.g., had a ≥ 30% reduction in liver fat). In addition, 27% of MGL-3196-treated patients had resolution of NASH compared to only 6% of placebo-treated patients.

  • Benzingalast month

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Lululemon Athletica inc. (NASDAQ: LULU ) stock was ...